Q-omics provides the consensus-scored FITM1 profile across patient tissues and cancer cell-line models. FITM1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, FITM1 is differentially expressed in 14, with the highest sampling consensus in LIHC. Additionally, FITM1 RNA expression shows 17,314 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UCEC, LIHC, and THYM as cancer lineages where FITM1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FITM1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FITM1 survival associations across molecular data types. FITM1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FITM1 RNA expression–survival associations across cancer types. High FITM1 expression shows favorable associations in UCEC, SCLC, CESC, BLCA, MESO and LIHC. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .005). Together, the overview and detailed table identify UCEC as the clearest survival context for FITM1 RNA expression.
This table summarizes FITM1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 2. The strongest signals are observed in LIHC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for FITM1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FITM1 shows lower tumor expression in LIHC, KICH, LUAD, KIRC, HNSC and BLCA. The LIHC box plot shows higher FITM1 RNA expression in normal versus tumor tissue (log2 FC = −1.953, t-test p < 0.001).
This table shows molecular features associated with FITM1 in patient tissues and cancer cell lines. In patient samples, FITM1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, FITM1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and SOFT_TISSUE.
